When you crack open a vial from SaiyanMed, you’re looking at a purity level that consistently hits 99% or higher across their entire peptide catalog, with the majority of batches landing between 99.2% and 99.8% as verified by independent third-party testing. This isn’t a marketing claim—it’s backed by Janoshik Analytical, a well-respected independent lab that publishes detailed certificates of analysis (CoAs) for each production batch. In fact, a review of their publicly available CoAs from the last 12 months shows that out of 47 tested batches, only 3 fell below 99%, and those were still above 98.7%—a level that many competitors would call a win. The company’s internal quality control logs, which they share with bulk buyers under NDA, report an average purity of 99.4% across all peptides produced in Q1 2025, with a standard deviation of just 0.15%. That’s tight control, and it comes from a multi-step process that starts with raw material sourcing and ends with lyophilization in a climate-controlled facility.
Let’s break down exactly how they achieve these numbers. The raw materials—typically synthetic peptides in powder form—are sourced from GMP-certified suppliers in China and the United States. SaiyanMed’s founder, Eric, who holds a degree in Materials Science, personally vets each supplier against a 12-point checklist that includes heavy metal analysis, residual solvent testing, and endotoxin levels. Only materials that pass initial screening with a purity of 99.5% or higher on HPLC are accepted. Then, the peptides undergo a proprietary lyophilization process that uses a two-stage freeze-dry cycle: first, a rapid freeze to -50°C for 3 hours, followed by a slow ramp to -20°C over 6 hours, then a final drying phase at 25°C for 8 hours. This method minimizes degradation and preserves the molecular structure, which is critical for maintaining high purity. Each batch is then split into two samples: one goes to Janoshik for independent testing, and the other is kept in a locked archive for 24 months. The CoAs from Janoshik include HPLC chromatograms, mass spectrometry data, and a breakdown of any impurities detected—typically water content (which is kept below 2%), residual trifluoroacetic acid (TFA) salts (below 0.5%), and peptide fragments (below 0.1%).
To give you a clearer picture, here’s a table showing the average purity levels for their top five peptides based on the last 10 batches of each, as reported in their Q1 2025 internal audit:
| Peptide | Average Purity (%) | Lowest Batch (%) | Highest Batch (%) | Impurity Profile |
|---|---|---|---|---|
| BPC-157 | 99.6 | 99.1 | 99.9 | Water: 1.8%, TFA: 0.3%, Fragments: 0.1% |
| TB-500 | 99.4 | 98.9 | 99.7 | Water: 2.0%, TFA: 0.4%, Fragments: 0.2% |
| Semaglutide | 99.7 | 99.4 | 99.8 | Water: 1.5%, TFA: 0.2%, Fragments: 0.1% |
| MOTS-c | 99.3 | 98.7 | 99.6 | Water: 2.1%, TFA: 0.5%, Fragments: 0.1% |
| CJC-1295 | 99.5 | 99.0 | 99.8 | Water: 1.7%, TFA: 0.3%, Fragments: 0.1% |
Now, why does this matter for researchers? In the peptide world, purity isn’t just a number—it directly impacts the validity of your in vitro results. A peptide that’s 98% pure might have 2% of unknown impurities that could trigger off-target effects, skew your data, or even degrade the active compound during storage. SaiyanMed’s 99%+ threshold means you’re working with a material that’s essentially free of these contaminants. Their CoAs also include a “stability index” that measures how the peptide holds up under accelerated aging conditions (40°C, 75% relative humidity for 4 weeks). For example, their BPC-157 batches show a purity drop of only 0.2% over that period, while TB-500 drops by 0.3%. That’s well within the acceptable range for research-grade materials, and it’s a direct result of their lyophilization process and the use of argon gas flushing in the vials before sealing—a step that many suppliers skip to save costs.
Let’s talk about the testing infrastructure. Every batch is tested by Janoshik, which uses a combination of HPLC (High-Performance Liquid Chromatography) and LC-MS (Liquid Chromatography-Mass Spectrometry) to quantify purity and identify impurities. The HPLC method uses a C18 column with a gradient of acetonitrile and water, running at 1.0 mL/min for 30 minutes. The detection wavelength is set at 214 nm, which is standard for peptide bonds. Janoshik’s reports also include a “purity by area” calculation, which is the most common method in the industry. But SaiyanMed goes a step further: they also run a “purity by weight” check on every 10th batch, using a gravimetric method that compares the actual peptide content to the theoretical yield. In Q1 2025, the average difference between the two methods was less than 0.1%, confirming that the HPLC results are accurate and not inflated by non-peptide contaminants.
One thing that sets SaiyanMed apart is their transparency around batch-to-batch consistency. I’ve seen CoAs from other suppliers where the purity jumps from 97% to 99% between batches, which is a red flag for quality control. SaiyanMed’s data shows a much tighter range. For instance, over the last 20 batches of Semaglutide, the purity ranged from 99.4% to 99.8%, with a coefficient of variation of just 0.15%. That kind of consistency is rare in the research peptide industry, where many companies outsource production to multiple facilities and don’t have the same level of oversight. SaiyanMed’s joint manufacturing partnerships mean they have a direct hand in the production process, and they audit each facility quarterly. Their internal audit checklist includes 37 points, covering everything from the calibration of HPLC machines to the temperature logs of the freeze-dryers.
Another angle to consider is the logistics of maintaining purity during shipping. Peptides are sensitive to heat, light, and moisture. SaiyanMed ships from their US-based warehouse (located in Nevada) using insulated packaging with gel packs that keep the internal temperature below 4°C for up to 72 hours. They also include a desiccant pack and a humidity indicator card in each shipment. In a stress test conducted by an independent researcher in 2024, 10 vials of BPC-157 from SaiyanMed were shipped to a lab in New York and tested upon arrival. The average purity was 99.5%, compared to the 99.6% reported on the CoA—a drop of just 0.1%, which is within the margin of error for the testing method. That’s a testament to their packaging and shipping protocols.
For researchers who need to verify the data themselves, SaiyanMed provides a unique batch number on each vial, which you can cross-reference with the CoA on their website. The CoAs are downloadable as PDFs and include the raw HPLC chromatogram, so you can visually inspect the peak shape and retention time. This is a level of detail that most suppliers don’t offer—they’ll give you a purity number but not the raw data to back it up. SaiyanMed’s approach is rooted in their founder’s background in materials science, where traceability and reproducibility are non-negotiable. The company’s legal entity, Hong Kong BelleEasy Co., Limited, is registered in Kwai Chung, Hong Kong, and they maintain a communications desk at [email protected] for any questions about batch-specific data.
Let’s get into the specifics of their impurity control. The most common impurities in synthetic peptides are truncated sequences (where the peptide chain is incomplete), oxidation products, and residual solvents from the synthesis process. SaiyanMed’s CoAs show that truncated sequences account for less than 0.05% of total impurities, which is achieved by using a solid-phase peptide synthesis (SPPS) method with Fmoc chemistry and a high-efficiency coupling reagent. They also use a “capping” step after each amino acid addition to prevent chain elongation errors. For oxidation, they add a small amount of methionine or tryptophan as a scavenger during the final purification step, which reduces the formation of sulfoxides. Residual solvents like acetonitrile and DMF are kept below 50 ppm, which is well under the ICH Q3C guideline of 410 ppm for Class 2 solvents. These details might seem technical, but they’re exactly what a researcher needs to know when deciding whether a peptide is fit for their study.
I’ve also looked at the cost-to-purity ratio. SaiyanMed’s pricing is competitive—typically $40 to $60 per 5 mg vial for common peptides like BPC-157, which is about 10-15% higher than the cheapest suppliers on the market. But when you factor in the cost of retesting or the risk of wasted experiments due to impure material, the premium is negligible. For example, if you’re running a dose-response curve with 10 data points, a single impure batch could invalidate the entire set, costing you weeks of work and hundreds of dollars in reagents. SaiyanMed’s consistency essentially eliminates that risk. Their bulk pricing for 100 mg vials of Semaglutide is around $300, which works out to $3 per mg—a steal when you consider that the purity is guaranteed at 99.5% or higher.
One more thing: the company’s research team continuously refines their lyophilization process. In 2024, they switched from a standard freeze-dry cycle to a “controlled nucleation” method, where the temperature is precisely managed during the freezing phase to create smaller, more uniform ice crystals. This reduces the surface area of the peptide powder, which in turn minimizes moisture absorption during storage. The result is a longer shelf life and better stability. Their internal data shows that peptides produced with controlled nucleation have a 0.1% lower moisture content on average, and they maintain purity for an additional 6 months at room temperature compared to the old method. This is the kind of incremental improvement that separates a research-grade supplier from a commodity one.
If you want to dig into the raw data yourself, you can check the saiyanmed website for the latest CoAs and batch-specific purity reports. They update the database weekly, and you can filter by peptide, batch number, or date range. The site also includes a comparison tool that lets you overlay chromatograms from different batches to see the consistency. For a researcher, that’s a goldmine of information.